Novo Nordisk's Pipeline Puzzle: A Warning Sign for Investors The latest setback for Novo Nordisk has sent shockwaves through Wall Street after its experimental heart medicine, ziltivekimab, failed to meet expectations in a late stage trial.
The company's shares plummeted as much as 10% on Friday.
Analysts are sounding alarms about the significance of this failure, despite attempts by Novo Nordisk's chief scientific officer, Martin Holst Lange, to downplay its importance.